Definitive Contract 75F40119C10018
Award Date
5/16/19
Potential Completion Date
5/19/21
Potential Value
$506K
Federal Agency
Food and Drug Administration
Awardee
Uppsala Universitet
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Food and Drug Administration (FDA) awarded a $527,318.00 definitive contract to Uppsala Universitet, a Swedish educational institution, to conduct research and development on model-integrated strategies for bioequivalence evaluation of drugs with high variability and/or long half-life. This contract was awarded under the FDA's Broad Agency Announcement, which seeks proposals to advance regulatory science in various areas. The contract has no set-aside designation and is intended to support...
This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Connecticut for "Assessing Long-Acting Injectable Formulations Using In Vivo Imaging". The potential value of the contract is $1,131,742.00 and it has a completion date of September 29, 2024. The contract is not set aside for a specific business category. Under this contract, the University of Connecticut is conducting research and analysis on...
This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to the Universitat ST. Gallen, doing business as Hochschule FÜR Wirtschafts-, Rechts- UND Sozialwissenschaften (Hsg), an educational institution. The contract is a Firm Fixed Price definitive contract with a potential value of $764,418.19 and a completion date of September 29, 2023. The contract was awarded under the FDA's Broad Agency Announcement (BAA) for Advanced Regulatory...
This is a $500,000 firm-fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to the University of Florida (UF) Division of Sponsored Research for a pharmacokinetic comparison study of locally acting orally inhaled drug products. The contract does not have a set-aside designation, indicating UF competed for and was awarded the contract based on its extensive research capabilities. UF is a major research institution that provides a wide range of goods and services to...
This federal contract award, identified as HHSF223201610099C, was made by the Food and Drug Administration (FDA) to the University of Florida (UF) Division of Sponsored Research. The contract, valued at $764,975.37, is for a Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products. This work falls under the FDA's Broad Agency Announcement (BAA) program for this research area. The contract is a definitive, cost-no-fee contract, with a performance period ending on March 22,...
The Department of Health and Human Services Food and Drug Administration awarded a $906,628.80 firm fixed price definitive contract to Universitat ST. Gallen, doing business as Hochschule Für Wirtschafts-, Rechts- und Sozialwissenschaften, to address the Broad Agency Announcement FY23C2DWP1: Predictive Continuous Improvement Acceleration towards Performance Based Regulations and Oversight. The contract responds to the FY23 FDA Broad Agency Announcement for Advanced Research and Development of...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $313,326 Firm Fixed Price contract to the University of Wisconsin System, operating through its University of Wisconsin - Madison division. The contract was awarded under a Broad Agency Announcement (BAA) for the "Development of Modernized Acinetobacter Baumannii Susceptibility Guidance for Recommended Antimicrobial Agents Using Pharmacometric Approaches". This contract is not associated with...
The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to the Regents of the University of Michigan for $1,482,306.00. The contract is to conduct research on the influence of raw materials, manufacturing variables, and storage conditions on the release performance of long-acting release microsphere products. The contract does not have a set-aside designation. The University of Michigan is a U.S. state government educational...
The Department of Health and Human Services Food and Drug Administration awarded a firm fixed-price purchase order to The Regents of the University of California, San Francisco (UCSF) for the Center for Drug Evaluation and Research (CDER) - Office of Executive Programs (OEP) Division of Learning and Organizational Development (DLOD) Drug Development and Regulatory Sciences Course. The $175,000.00 contract has a completion date of December 31, 2022. UCSF, a U.S. state government and educational...
The Department of Health and Human Services Food and Drug Administration awarded a firm-fixed-price definitive contract to the University of Bath, a private university located in the United Kingdom, with a potential value of $353,765.00. The contract, which does not have a set-aside designation, is for research and educational services to be completed by August 31, 2022. Based on the vendor's past performance, the University of Bath has provided research services in areas such as physics,...